Elixira:
Cancer Prevention
Beyond Cancer Vaccines

– A Tribute To History and Commitment To The Path Forward

Author: Tess Fries
Affiliation: Inventor and Founder of Elixira; Founder of Nanoism
Contact: contact@elixira.tech
Date: October 2025
DOI: https://doi.org/10.5281/zenodo.17238553

Abstract

Invented and founded by Tess Fries in 2025, Elixira is a breakthrough patent-pending AI-guided nanomedicine platform designed for autonomous, lifelong cancer prevention. Its feasibility has been independently documented by a leading Contract Research Organization (CRO), and all underlying technologies are scientifically validated. Elixira embodies the world's first form of preventive nanomedicine, inaugurating a new medical field called Nanoism, which signifies the convergence of nanotechnology, artificial intelligence, and autonomous energy systems into a self-sustaining paradigm of lifelong, proactive disease prevention.

From the first cancer-preventive vaccines to the dawn of autonomous nanomedicine, prevention has entered a new era. Cancer vaccines represent a historic milestone in lifesaving medical technology, having laid the foundation for cancer prevention through the HBV and HPV vaccines. This paper establishes Elixira as a next-generation framework for cancer prevention, transcending the advances achieved through cancer vaccines and highlighting the distinct strengths and differences between Elixira and cancer vaccines. It demonstrates how Elixira advances cancer prevention into a new era defined by continuous, autonomous lifelong protection, supported by an ethically driven business model to ensure cancer prevention becomes free to patients and equally accessible across borders — in the service of fundamental human rights to health and equality before profit.

Keywords:
Elixira, Nanoism, Cancer Prevention, Cancer Vaccines, Nanomedicine, Immunology, Oncology, AI, Nanotechnology, Preventive Medicine, Global Health, Autonomous Medicine, Lifelong Health

1. Introduction: Cancer Vaccines – A Milestone in the History of Medicine

Cancer vaccines have profoundly reshaped the trajectory of human health in modern medicine, proving that prevention can alter the course of some of the world's deadliest diseases.
Cancer vaccines, in particular, represent one of the most transformative achievements in preventive oncology. They gave proof that medicine can do more than treat disease—it can prevent it.

History reveals a long lineage of triumphs in health, where vaccines have transformed the conditions of human life and saved countless lives. A historical medical breakthrough occurred in the 1980s, when the introduction of the hepatitis B virus (HBV) vaccine provided the first proof that a vaccine could prevent a major cancer (Chang et al., 1997; Chang et al., 2009; Cui et al., 2023). This milestone, as demonstrated in Taiwan (Chang et al., 1997; Chang et al., 2009), was followed by a dramatic worldwide reduction in liver cancer. Building on these successes, the introduction of the human papillomavirus (HPV) vaccine in 2006 has led to sharp declines in HPV-related malignancies across populations (Drolet et al., 2019). Today, with HPV vaccination programs widely available in schools, an entire generation can now grow up without this threat.

The impact of these vaccines has been extraordinary. Historically, cervical cancer ranked second only to breast cancer in many low- and middle-income countries (Parkin et al., 2005; Quinn et al., 1999). With HPV vaccination and screening, incidence has declined sharply, and several countries are now on a path toward elimination (WHO, 2022; Brisson et al., 2020).In Taiwan, childhood liver cancer incidence was reduced by up to 80% within two decades because of universal HBV vaccination (Chang et al., 2009). This represents not just numbers and statistics—but millions of lives saved, families preserved, and futures secured.

Cancer vaccines are more than biomedical tools; they are historical milestones. They shifted the paradigm of medicine by proving that cancer prevention is possible and thereby opened the door to a new way of thinking in healthcare—one in which prevention can surpass treatment as the primary objective, where we prevent before we treat, and protect before we resolve (Hood & Friend, 2011).

On this foundation of successes, we are humbly led to today's medical advancements.
While cancer vaccines have long pioneered the landscape of medicine, they leave room for the broader landscape of cancers to be addressed. Because vaccines target specific virus-driven cancers, their effectiveness depends on widespread immunization before exposure. The next natural leap in medical history is therefore to close this gap and, by standing on the shoulders of giants, create a universal, autonomous system of prevention—one that protects every person, across all cancer types, regardless of age or immune status, for life.
It is no longer a question of *if* prevention can surpass treatment, but *when*.
Cancer prevention has already proved successful in preventing disease, and it is now time for the next paradigm in preventive medicine, through the first-ever preventive nanomedicine platform, designed for lifelong cancer prevention.

Elixira: A New Paradigm in Cancer Prevention – Closing the Gaps in Cancer Vaccines

With cancer still remaining the world's second leading cause of death, new approaches are urgently required (World Health Organization, 2022; American Cancer Society, 2024; Barta et al., 2024; Didkowska et al., 2021).

While cancer vaccines are invaluable, they are currently limited to virus-associated cancers and depend heavily on the host immune system for efficacy, making them unsuitable as a universal solution for preventing all cancers before they emerge. Elixira, developed within the emerging discipline of Nanoism, addresses this unmet need by offering a universal and lifelong form of cancer prevention.

Elixira closes the following gaps left by cancer vaccines:

- Restricted scope: Cancer vaccines are only against virus-induced cancers, while Elixira provides protection across all cancer types, including viral, genetic, sporadic, and age-related malignancies.

- Waning immunity over time: Cancer vaccines can provide long-term protection, but immunity may decline and boosters may be required, whereas Elixira functions as a lifelong, self-sustaining system that maintains efficacy without repeated doses or external interventions.

- Population gaps: Cancer vaccine uptake is uneven across regions, reducing global impact, while Elixira is designed for universal deployment through equal access across borders, independent of vaccination campaigns or healthcare infrastructure disparities.

- Non-universal reach: Cancer vaccines for the majority of sporadic or genetically driven cancers don't exist, while Elixira addresses all underlying oncogenic mechanisms, extending prevention to cancers beyond the reach of vaccines.

- Immune dependency: Cancer vaccines rely on the host immune system to be effective, while Elixira functions independently of immune status, providing protection even in immunocompromised or elderly populations.

- Cost barriers: Cancer vaccines can be costly and are not always freely available, especially in low- and middle-income countries, while Elixira is structured for universal accessibility, designed to be free at the point of care through a strictly ethically defined licensing framework and deployment model.

Key Distinctions: Elixira, in contrast, is designed for lifelong, universal protection across all cancers—independent of immunity, boosters, or cost—and structured according to an ethically driven business model to be freely accessible to everyone at the point of care.

4. Comparative Analysis: Elixira vs Cancer Vaccines

Elixira represents not just a technology, but a new paradigm in preventive medicine.
To understand the scope of this paradigm shift, a direct comparison between Elixira and cancer vaccines is essential. These distinctions matter because they transform prevention from selective and potentially time-bound protection into a universal, lifelong, and autonomous shield.

Dimensions	**Elixira**	**Cancer Vaccines**
Scope	Universal, across all cancer types (viral, genetic, sporadic, age-related)	Virus-induced cancers only (e.g., HPV, HBV)
Duration	Lifelong, one-time injection	Protection may wane over time, boosters sometimes required
Mechanism	Autonomous nanobots detect and neutralize malignant cells, independent of immune status	Immune priming against viral antigens
Timing of Action	Prevents malignant transformation at cellular level	Prevents infection leading to cancer
Population Coverage	Universal deployment, equal access across borders, inherent protection once injected	Uptake uneven across regions, dependent on vaccination rates
Adaptability	AI-driven, adaptive to evolving cancer phenotypes	Static immune memory
Accessibility & Cost	Free at point of care, ensured through ethical licensing and deployment model	Variable, depends on healthcare systems and resources

5. Implications for Preventive Medicine

Through Elixira, the future of cancer prevention is no longer constrained by biology or geography, but defined by universal protection delivered through a sustainable, globally accessible, and ethically governed deployment framework.

If vaccines represent the first generation of preventive oncology, Elixira marks the dawn of the second generation—lifelong, universal prevention.

This shift carries implications for global health systems:

- Equity: Universal protection regardless of geography or infection prevalence.
- Economics: Prevention at scale reduces treatment costs and burden on healthcare.
- Ethics: Ensures access to lifelong protection as a human right rather than a privilege.

By not only transcending cancer prevention as a groundbreaking lifesaving technology, but also embedding ethics in its deployment model, Elixira becomes the world's first preventive nanomedicine platform to provide lifelong protection across all cancer types, all regions, all ages, and all immune statuses—free to the patient. As the first embodiment of Nanoism, Elixira inaugurates a new field of preventive nanomedicine, defined by autonomy, universality, and ethical accessibility, while opening the door to a wide range of future disease prevention applications through Elixira's core platform. Elixira is shaping a new era where selective prevention transforms into universal prevention that precedes treatment, marking the beginning of Nanoism as a new discipline in medicine and establishing a new long awaited standard in healthcare: lifelong health.

6. Conclusion

Through cancer vaccines it has been proven that prevention is possible, but as with all groundbreaking innovations, they leave room for improvement. Elixira expands this frontier, offering a universal, lifelong, and autonomous solution. Within the framework of Nanoism, Elixira elevates preventive medicine beyond the limits of viral origins, inaugurating a new paradigm with the capacity to eradicate the global burden of cancer.

Cancer vaccines are the cornerstone of a profoundly significant path on which Elixira now humbly carries the torch forward.

Author’s Note

With my deepest and unending respect, it is important to note that we all stand in gratitude to cancer vaccines, for in 1981 – a historic year in medicine – the scientific community was given proof, through the approval of the first HBV vaccine, that cancer can, in fact, be prevented. This understanding reached global recognition in 1986, when an improved version was approved, marking the moment when cancer prevention first captured worldwide attention (Chang, 2023). That milestone paved the way for June 8, 2006 – another defining moment in medical history – when the world witnessed, through the approval of the HPV vaccine (Markowitz et al., 2007) and building on the precedent set by the hepatitis B vaccines in the 1980s, that cancer prevention was not only possible but achievable on a global scale. This led to the realization that *humanity need not live at the mercy of cancer* — and Elixira gratefully builds upon this path, never forgetting those who first proved to us that cancer can be eliminated by design, and for this legacy — remaining forever in gratitude.

Thank you.

References

Chang, M. H., Chen, C. J., Lai, M. S., Hsu, H. M., Wu, T. C., Kong, M. S., ... & Chen, D. S. (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. *New England Journal of Medicine, 336*(26), 1855–1859. https://doi.org/10.1056/NEJM199706263362602

Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lee, C. M., Lin, S. M., ... & Chen, D. S. (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study. *Journal of the National Cancer Institute, 101*(19), 1348–1355. https://doi.org/10.1093/jnci/djp288

Cui, F., Shen, L., Li, L., Wang, F., Zhang, J., Liang, X., ... & Wang, F. (2023). Long-term protection of neonatal hepatitis B vaccination against primary liver cancer: 37-year follow-up of Qidong hepatitis B intervention study. *Vaccines, 12*(4), 439. https://doi.org/10.3390/vaccines12040439

Drolet, M., Bénard, É., Pérez, N., Brisson, M., & HPV Vaccination Impact Study Group. (2019). Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. *The Lancet*, 394(10197), 497–509. https://doi.org/10.1016/S0140-6736(19)30298-3

Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. *CA: A Cancer Journal for Clinicians, 55*(2), 74–108. https://doi.org/10.3322/canjclin.55.2.74

Quinn, M., Babb, P., Jones, J., & Allen, E. (1999). Effect of screening on incidence of and mortality from cancer of the cervix in England: Evaluation based on routinely collected statistics. *BMJ, 318*(7188), 904–908. https://doi.org/10.1136/bmj.318.7188.904

World Health Organization. (2022). Cervical cancer. *WHO Fact Sheets.* https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Boily, M. C., & the HPV-FRAME Study Group. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: A comparative modelling analysis in 78 low-income and lower-middle-income countries. *The Lancet, 395*(10224), 575–590. https://doi.org/10.1016/S0140-6736(20)30068-4

Hood, L., & Friend, S. H. (2011). Predictive, personalized, preventive, participatory (P4) cancer medicine. *Nature Reviews Clinical Oncology*, 8(3), 184–187. https://pubmed.ncbi.nlm.nih.gov/21364692/

World Health Organization. (2022). *Cancer*. WHO. https://www.who.int/news-room/fact-sheets/detail/cancer

American Cancer Society. (2024). *Global cancer facts & figures 5th edition*. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf

Barta, S. K., et al. (2024). Global burden of cancer and associated risk factors. *Journal of Hematology & Oncology, 17*(1), 65. https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01640-8

Didkowska, J., Wojciechowska, U., & Olasek, P. (2021). One in four dies of cancer. Questions about the epidemiology of cancer. *Nowotwory. Journal of Oncology, 71*(2), 85–92. https://pubmed.ncbi.nlm.nih.gov/34019159/

Chang, M.-H. (2023). Hepatitis B virus and cancer prevention. *Frontiers in Immunology, 14,* 1098432. https://doi.org/10.3389/fimmu.2023.1098432

Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., & Unger, E. R. (2007). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report (MMWR), 56*(RR-2), 1–24. https://pubmed.ncbi.nlm.nih.gov/17380109/